Already allied with Takeda, Egle raises €40M for its ‘starving’ immunotherapy


In less than two years, Egle Therapeutics launched, partnered with Takeda Pharmaceutical, and found its first cancer targets. Now the startup has €40M in Series A financing to further develop its new approach to modulating regulatory T cells as a way of treating autoimmune diseases and cancer.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.